Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring (Jan 2020)

The Alzheimer's Biomarker Consortium‐Down Syndrome: Rationale and methodology

  • Benjamin L. Handen,
  • Ira T. Lott,
  • Bradley T. Christian,
  • Nicole Schupf,
  • Sid OBryant,
  • Mark Mapstone,
  • Anne M. Fagan,
  • Joseph H. Lee,
  • Dana Tudorascu,
  • Mei‐Cheng Wang,
  • Elizabeth Head,
  • William Klunk,
  • Beau Ances,
  • Florence Lai,
  • Shahid Zaman,
  • Sharon Krinsky‐McHale,
  • Adam M. Brickman,
  • H. Diana Rosas,
  • Annie Cohen,
  • Howard Andrews,
  • Sigan Hartley,
  • Wayne Silverman,
  • the Alzheimer's Biomarker Consortium‐Down Syndrome (ABC‐DS)

DOI
https://doi.org/10.1002/dad2.12065
Journal volume & issue
Vol. 12, no. 1
pp. n/a – n/a

Abstract

Read online

Abstract Introduction Adults with Down syndrome (DS) are at exceptionally high risk for Alzheimer's disease (AD), with virtually all individuals developing key neuropathological features by age 40. Identifying biomarkers of AD progression in DS can provide valuable insights into pathogenesis and suggest targets for disease modifying treatments. Methods We describe the development of a multi‐center, longitudinal study of biomarkers of AD in DS. The protocol includes longitudinal examination of clinical, cognitive, blood and cerebrospinal fluid‐based biomarkers, magnetic resonance imaging and positron emission tomography measures (at 16‐month intervals), as well as genetic modifiers of AD risk and progression. Results Approximately 400 individuals will be enrolled in the study (more than 370 to date). The methodological approach from the administrative, clinical, neuroimaging, omics, neuropathology, and statistical cores is provided. Discussion This represents the largest U.S.‐based, multi‐site, biomarker initiative of AD in DS. Findings can inform other multidisciplinary networks studying AD in the general population.

Keywords